Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ORIC

ORIC Pharmaceuticals Inc

May 07 • 04:00PM ET

9.61

Dollar change +0.24
Percentage change 2.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM DWAS IWN IBB VTWO DFAC PTH LABU

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	40.52%	Shs Outstand	54.87M	Perf Week	8.83%
Market Cap	647.91M	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-0.38%	Shs Float	40.10M	Perf Month	-10.60%
Income	-101.76M	PEG	-	EPS next Q	-0.41	Inst Own	61.65%	Short Float	23.50%	Perf Quarter	-21.87%
Sales	0.00M	P/S	-	EPS this Y	11.40%	Inst Trans	-0.30%	Short Ratio	16.05	Perf Half Y	35.73%
Book/sh	4.87	P/B	1.97	EPS next Y	-9.76%	ROA	-35.25%	Short Interest	9.42M	Perf Year	88.06%
Cash/sh	4.70	P/C	2.05	EPS next 5Y	-	ROE	-38.30%	52W Range	4.90 - 16.65	Perf YTD	4.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.33%	ROI	-30.96%	52W High	-42.28%	Beta	1.19
Dividend TTM	-	Quick Ratio	21.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	96.12%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	21.31	EPS Y/Y TTM	17.36%	Oper. Margin	0.00%	RSI (14)	46.36	Volatility	6.97% 6.63%
Employees	100	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.11	Target Price	18.88
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	30.06%	Payout	-	Rel Volume	0.64	Prev Close	9.37
Sales Surprise	-	EPS Surprise	13.79%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	587.13K	Price	9.61
SMA20	4.33%	SMA50	-19.21%	SMA200	4.01%	Trades		Volume	375,096	Change	2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7
Jul-06-21	Upgrade	Citigroup	Neutral → Buy	$34
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$34
Aug-13-20	Initiated	Robert W. Baird	Outperform	$45
Aug-06-20	Upgrade	Citigroup	Neutral → Buy	$35
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
May-19-20	Initiated	JP Morgan	Overweight	$40
May-19-20	Initiated	Jefferies	Buy	$40
May-19-20	Initiated	Guggenheim	Buy	$45
May-19-20	Initiated	Citigroup	Neutral	$35

Show Previous Ratings

May-06-24 09:54PM	ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:15PM	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC (GlobeNewswire)
Apr-08-24 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
04:30PM	Loading…
Apr-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-26-24 09:55AM	How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3% (Zacks)
Mar-12-24 09:01PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-11-24 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Mar-08-24 05:01PM	ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com) -5.78%
Mar-06-24 04:30PM	ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.07%
Feb-14-24 04:30PM	ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit (GlobeNewswire)
02:23AM	Loading…
Feb-09-24 02:23AM	ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com)
Feb-08-24 08:50AM	Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why (Zacks)
Feb-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 03:05PM	Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc (GuruFocus.com)
Jan-31-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-24 08:50AM	Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-22-24 08:30AM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
Jan-09-24 12:31PM	Final Boarding Call: 3 Stocks Set for a Sky-High Surge (InvestorPlace)
Jan-08-24 08:30AM	ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-02-24 04:30PM	ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-23 12:00PM	Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development (GlobeNewswire) -5.30%
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-01-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.44%
Nov-06-23 05:22PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com)
04:10PM	Loading…
04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-03-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-02-23 09:00AM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-21-23 07:30AM	Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile (GlobeNewswire)
Oct-17-23 04:30PM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023 (GlobeNewswire)
Oct-16-23 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-06-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-23 04:30PM	ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-01-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-30-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-04-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-23 01:04PM	Why Shares of Oric Pharmaceuticals Jumped Monday (Motley Fool) +27.73%
08:30AM	ORIC Pharmaceuticals Announces $85 Million Private Placement Financing (GlobeNewswire)
Jun-02-23 04:15PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-31-23 04:10PM	ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-28-23 09:28AM	We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth (Simply Wall St.)
May-08-23 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
May-05-23 04:15PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-25-23 04:30PM	ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -6.88%
06:35AM	The 7 Best Biotech Stocks for Personalized Medicine Investors (InvestorPlace)
Apr-18-23 04:15PM	ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.50%
Mar-31-23 08:40AM	One ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) insider upped their stake by 128% in the previous year (Simply Wall St.)
Mar-29-23 07:53PM	Charts Point to Higher Highs, Says Oppenheimer. Heres a Stock With Over 100% Upside Potential (TipRanks) +5.92%
Mar-16-23 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates (GlobeNewswire) +15.24%
03:10AM	6 big analyst picks: Stifel says FedEx stock is a buy \| Pro Recap (Investing.com)
Mar-14-23 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-06-23 04:15PM	ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-03-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.14%
Feb-01-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.01%
04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace)
Jan-27-23 08:41AM	ORIC Pharmaceuticals, Inc.'s (NASDAQ:ORIC) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures (Simply Wall St.)
Jan-09-23 08:00AM	ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones (GlobeNewswire)
Jan-03-23 04:30PM	ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-22 11:35AM	ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study (Zacks) +59.67%
08:38AM	Oric's stock rallies on multiple myeloma deal with Pfizer (MarketWatch)
07:54AM	ORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer (Benzinga)
Dec-21-22 05:48PM	ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer (GlobeNewswire)
Dec-19-22 08:13AM	Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-13-22 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +7.76%
Nov-08-22 04:10PM	ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update (GlobeNewswire)
Nov-03-22 09:00AM	ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.99%
Oct-22-22 08:36AM	Bullish insiders at ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) loaded up on US$2.1m of stock earlier this year (Simply Wall St.)
Oct-21-22 12:06PM	AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition (Zacks)
Oct-14-22 09:37AM	GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults (Zacks) -11.78%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-07-22 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.80%
10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks)
Sep-28-22 01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-22-22 10:50AM	Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks)
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks)
08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks)
Sep-07-22 01:31PM	IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study (Zacks)
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-01-22 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-25-22 11:53AM	AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs (Zacks)
11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-23-22 01:53PM	Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe (Zacks)
Aug-20-22 08:28AM	With 61% ownership of the shares, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is heavily dominated by institutional owners (Simply Wall St.)
Aug-16-22 10:09AM	Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 (Zacks)
Aug-11-22 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update (GlobeNewswire)
Jul-11-22 11:00AM	We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely (Simply Wall St.) -9.31%
Jun-02-22 04:10PM	ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 04:10PM	ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +10.57%
May-15-22 08:06AM	Jacob Chacko Is The President of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) And They Just Picked Up 128% More Shares (Simply Wall St.)
Apr-12-22 04:05PM	ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-31-22 08:33AM	7 Stocks That Insiders Are Buying Now. Should You? (InvestorPlace)

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chacko Jacob	PRESIDENT AND CEO	Mar 06 '24	Sale	16.21	40,000	648,380	728,544	Mar 08 04:20 PM
Chacko Jacob	PRESIDENT AND CEO	Feb 07 '24	Sale	12.29	26,042	320,186	768,544	Feb 08 08:01 PM
Chacko Jacob	PRESIDENT AND CEO	Feb 06 '24	Sale	12.12	13,958	169,160	794,586	Feb 08 08:01 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '23	Option Exercise	0.00	14,042	0	29,091	Dec 19 07:42 PM
Chacko Jacob	President and CEO	Dec 15 '23	Option Exercise	0.00	38,667	0	823,083	Dec 19 07:39 PM
Chacko Jacob	President and CEO	Dec 15 '23	Sale	8.58	14,539	124,813	808,544	Dec 19 07:39 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '23	Sale	8.59	5,282	45,351	23,809	Dec 19 07:42 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '23	Sale	8.58	5,282	45,338	83,809	Dec 19 07:40 PM
Chacko Jacob	President and CEO	Jul 11 '23	Sale	8.01	5,156	41,287	780,652	Jul 11 09:28 PM
Chacko Jacob	President and CEO	Jul 10 '23	Sale	8.01	10,508	84,212	785,808	Jul 11 09:28 PM
Chacko Jacob	President and CEO	Jul 05 '23	Sale	8.01	4,336	34,711	796,316	Jul 07 04:35 PM
Chacko Jacob	President and CEO	Jun 26 '23	Sale	8.03	20,000	160,562	800,652	Jun 28 07:18 PM

Open in Screener

FDMT

4D Molecular Therapeutics Inc

May 07 • 04:00PM ET

26.80

Dollar change +0.04
Percentage change 0.15	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

FDMT 4D Molecular Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN IBB VTWO SCHA LABU DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	6.65%	Shs Outstand	51.16M	Perf Week	11.99%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-3.40	Insider Trans	-18.88%	Shs Float	47.75M	Perf Month	-6.78%
Income	-95.93M	PEG	-	EPS next Q	-0.74	Inst Own	73.67%	Short Float	20.60%	Perf Quarter	-19.30%
Sales	21.99M	P/S	62.35	EPS this Y	-13.58%	Inst Trans	0.28%	Short Ratio	11.46	Perf Half Y	131.03%
Book/sh	7.72	P/B	3.47	EPS next Y	-16.10%	ROA	-29.90%	Short Interest	9.83M	Perf Year	58.21%
Cash/sh	6.25	P/C	4.29	EPS next 5Y	-	ROE	-33.00%	52W Range	9.44 - 36.25	Perf YTD	32.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.35%	ROI	-28.05%	52W High	-26.07%	Beta	2.94
Dividend TTM	-	Quick Ratio	18.07	Sales past 5Y	111.29%	Gross Margin	74.42%	52W Low	183.90%	ATR (14)	1.57
Dividend Ex-Date	-	Current Ratio	18.07	EPS Y/Y TTM	17.81%	Oper. Margin	-477.24%	RSI (14)	51.91	Volatility	5.81% 6.09%
Employees	147	Debt/Eq	0.05	Sales Y/Y TTM	1014.45%	Profit Margin	-436.30%	Recom	1.09	Target Price	52.20
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	69.41%	Payout	-	Rel Volume	0.39	Prev Close	26.76
Sales Surprise	-100.75%	EPS Surprise	4.96%	Sales Q/Q	3940.80%	Earnings	Feb 29 AMC	Avg Volume	858.13K	Price	26.80
SMA20	4.74%	SMA50	-5.41%	SMA200	38.15%	Trades		Volume	334,995	Change	0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70
Jan-05-21	Initiated	BofA Securities	Buy	$47

Show Previous Ratings

Today 08:00AM	4DMT to Participate in Upcoming Investor Conference (GlobeNewswire)
May-01-24 10:01AM	4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +6.10%
08:00AM	4DMT Announces Presentations at ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 01:30AM	4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares (GuruFocus.com)
Mar-29-24 07:01PM	4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares (GuruFocus.com)
08:00AM	Loading…
Mar-28-24 08:00AM	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis (GlobeNewswire) -11.18%
Mar-04-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-02-24 04:32AM	4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 06:05PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4DMT Reports Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Feb-12-24 08:00AM	4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium 2024 (GlobeNewswire)
Feb-08-24 03:05AM	Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc (GuruFocus.com)
Feb-06-24 11:27PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Feb-05-24 04:05PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +84.62%
02:50PM	Why Is 4D Molecular (FDMT) Stock Up 85% Today? (InvestorPlace)
12:36PM	Loading…
12:36PM	4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes' (Reuters)
Feb-03-24 05:00PM	4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD (GlobeNewswire)
Jan-29-24 08:00AM	4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden (GlobeNewswire)
Jan-25-24 10:04PM	4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares (GuruFocus.com)
Jan-23-24 08:00AM	4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease (GlobeNewswire)
Jan-19-24 12:00PM	All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy (Zacks)
Jan-11-24 10:00AM	TurnCare, Inc. Announces John F. Milligan, PhD, former CEO of Gilead Sciences, joins Board of Directors (PR Newswire)
Jan-09-24 05:02AM	4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares (GuruFocus.com)
Jan-06-24 05:02AM	Andreas Halvorsen's Firm Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
05:02AM	Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc (GuruFocus.com)
Jan-04-24 08:00AM	4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates (GlobeNewswire)
Jan-03-24 08:01AM	4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases (GlobeNewswire) -5.08%
Dec-21-23 08:00AM	4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD (GlobeNewswire) +7.35%
Dec-04-23 08:00AM	4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference (GlobeNewswire)
Nov-15-23 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:19PM	Loading…
Nov-09-23 04:19PM	4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-01-23 04:00PM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-30-23 08:00AM	4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy (GlobeNewswire)
Oct-26-23 09:56AM	Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls (The Fly)
Oct-25-23 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC (GlobeNewswire)
Oct-23-23 08:00AM	4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD (GlobeNewswire)
Sep-12-23 04:05PM	4DMT Appoints Uneek Mehra as Chief Financial and Business Officer (GlobeNewswire)
Sep-07-23 04:05PM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD (GlobeNewswire)
Aug-09-23 06:15PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
08:22AM	Despite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 year (Simply Wall St.)
Jul-29-23 12:00PM	4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023 (GlobeNewswire)
Jul-17-23 04:05PM	4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data (GlobeNewswire)
Jul-10-23 07:30PM	Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets (PR Newswire)
Jun-08-23 09:53AM	4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why (Benzinga) +6.84%
Jun-07-23 04:10PM	4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting (GlobeNewswire)
Jun-01-23 08:00AM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 08:00AM	4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting (GlobeNewswire)
May-13-23 08:27AM	Institutional investors have a lot riding on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 44% ownership (Simply Wall St.)
May-12-23 06:02PM	Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeutics (GuruFocus.com) +5.98%
06:02PM	Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics (GuruFocus.com)
May-11-23 08:00AM	4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting (GlobeNewswire)
May-10-23 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-09-23 04:05PM	4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
08:25AM	Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-23 04:05PM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
06:27AM	4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains? (Zacks)
May-04-23 09:04PM	4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) -15.46%
04:08PM	4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Apr-27-23 04:29PM	What's Going On With 4D Molecular Therapeutics Stock Today (Benzinga) -19.79%
07:00AM	4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023 (GlobeNewswire)
Apr-24-23 08:00AM	Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas Short-Form Human Complement Factor H (GlobeNewswire)
08:00AM	4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy (GlobeNewswire)
Apr-14-23 04:23AM	4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Apr-13-23 08:00AM	4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer (GlobeNewswire) +11.15%
Apr-12-23 08:21AM	Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Mar-22-23 08:09AM	Heres Why 4D Molecular Therapeutics (FDMT) Stock Boosted in Q4 (Insider Monkey)
Mar-15-23 05:45PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.06%
04:05PM	4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire)
Mar-02-23 05:41AM	4D Molecular Therapeutics (NASDAQ:FDMT) shareholders have earned a 38% return over the last year (Simply Wall St.)
Feb-23-23 11:33AM	4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study (Benzinga) -6.77%
Feb-22-23 04:05PM	4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium (GlobeNewswire)
Feb-16-23 04:05PM	4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium (GlobeNewswire)
Feb-08-23 04:05PM	4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.52%
Feb-02-23 04:05PM	4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema (GlobeNewswire) +7.31%
Jan-30-23 12:54PM	BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target' (Benzinga)
Jan-09-23 09:00AM	4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs (GlobeNewswire) -10.18%
Dec-01-22 08:26PM	2 Strong Buy Stocks Goldman Sachs Predicts Will Surge at Least 40% (TipRanks)
Nov-21-22 04:05PM	4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference (GlobeNewswire) -5.05%
Nov-20-22 05:39AM	2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street (Motley Fool)
Nov-17-22 10:36AM	4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why (Zacks) +6.62%
Nov-14-22 02:07PM	4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial (Benzinga) +7.83%
07:30AM	4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD) (GlobeNewswire)
Nov-10-22 04:05PM	4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022 (GlobeNewswire) +12.75%
05:08AM	4D Molecular Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-09-22 04:05PM	4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) +6.41%
Nov-03-22 09:45AM	4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022 (GlobeNewswire) +7.76%
06:30AM	Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-26-22 04:05PM	4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022 (GlobeNewswire)
Sep-27-22 04:10PM	4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer (GlobeNewswire)
Sep-23-22 06:02AM	Shareholders in 4D Molecular Therapeutics (NASDAQ:FDMT) have lost 77%, as stock drops 12% this past week (Simply Wall St.)
Sep-20-22 04:15PM	4D Molecular Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-22 11:20AM	4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment (Benzinga) -8.27%
Aug-11-22 05:15PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:03PM	4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update (GlobeNewswire)
Jun-28-22 04:23PM	Biotech champion, QB3 leader Reg Kelly to retire (American City Business Journals)
Jun-02-22 04:02PM	4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The firm also offers product candidates focused on large market ophthalmology, pulmonology, and cardiology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bizily Scott	Chief Legal Officer	Apr 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 16 '24	Sale	25.74	1,750	45,045	1,737	Apr 18 08:48 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Option Exercise	12.54	8,153	102,224	9,890	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Apr 01 '24	Sale	31.78	8,153	259,102	1,737	Apr 03 07:18 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Option Exercise	25.98	5,833	151,541	7,570	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 27 '24	Sale	35.04	5,833	204,410	1,737	Mar 29 04:52 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Option Exercise	7.60	1,750	13,295	3,487	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Mar 18 '24	Sale	31.27	1,750	54,722	1,737	Mar 20 04:40 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Option Exercise	20.24	1,909	38,638	3,646	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 27 '24	Sale	30.00	1,909	57,270	1,737	Feb 29 06:01 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Option Exercise	7.60	1,750	13,295	3,487	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 16 '24	Sale	27.67	1,750	48,422	1,737	Feb 21 05:41 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Option Exercise	10.18	6,244	63,586	4,653	Feb 12 09:04 PM
Kirn David	Chief Executive Officer	Feb 08 '24	Sale	27.13	92,001	2,495,822	1,059,153	Feb 12 08:22 PM
Bizily Scott	Chief Legal Officer	Feb 08 '24	Sale	27.50	6,244	171,710	1,737	Feb 12 09:04 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Option Exercise	15.29	24,000	366,840	13,595	Feb 07 08:32 PM
Kim Robert Young	Chief Medical Officer	Feb 05 '24	Sale	30.05	24,552	737,788	1,043	Feb 07 08:32 PM
Kirn David	Chief Executive Officer	Jan 23 '24	Sale	18.41	5,696	104,851	1,151,154	Jan 25 04:59 PM
Kirn David	Chief Executive Officer	Jan 05 '24	Sale	19.57	28,237	552,478	1,156,850	Jan 08 04:19 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 04 '24	Sale	19.53	540,000	10,546,200	4,247,914	Jan 05 05:44 PM
Kirn David	Chief Executive Officer	Jan 04 '24	Sale	20.31	40,732	827,202	1,185,087	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 18 '23	Sale	18.13	4,702	85,243	1,225,819	Jan 08 04:19 PM
Kirn David	Chief Executive Officer	Dec 15 '23	Sale	17.27	28,632	494,432	1,230,521	Jan 08 04:19 PM
Bizily Scott	Chief Legal and HR Officer	Jun 08 '23	Option Exercise	8.04	3,750	30,150	5,487	Jun 12 06:23 PM
Bizily Scott	Chief Legal and HR Officer	Jun 08 '23	Sale	20.85	3,750	78,188	1,737	Jun 12 06:23 PM
Bizily Scott	Chief Legal and HR Officer	Jun 01 '23	Option Exercise	6.49	1,875	12,169	3,984	Jun 06 07:23 PM
Bizily Scott	Chief Legal and HR Officer	Jun 01 '23	Sale	18.31	2,247	41,143	1,737	Jun 06 07:23 PM
Moretti August J	Chief Financial Officer	May 15 '23	Option Exercise	9.41	3,000	28,230	11,045	May 16 08:52 PM
VIKING GLOBAL INVESTORS LP	10% Owner	May 09 '23	Buy	16.00	850,000	13,600,000	4,787,914	May 11 05:50 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ORIC

ORIC Pharmaceuticals Inc

FDMT

4D Molecular Therapeutics Inc

Upgrade your FINVIZ experience